BRPI0909936A2 - "composição para o envio transdérmico, em particular envio transdérmico iontoforético, de pelo menos um agente ativo catiônico ou um sal do mesmo" - Google Patents
"composição para o envio transdérmico, em particular envio transdérmico iontoforético, de pelo menos um agente ativo catiônico ou um sal do mesmo"Info
- Publication number
- BRPI0909936A2 BRPI0909936A2 BRPI0909936A BRPI0909936A BRPI0909936A2 BR PI0909936 A2 BRPI0909936 A2 BR PI0909936A2 BR PI0909936 A BRPI0909936 A BR PI0909936A BR PI0909936 A BRPI0909936 A BR PI0909936A BR PI0909936 A2 BRPI0909936 A2 BR PI0909936A2
- Authority
- BR
- Brazil
- Prior art keywords
- transdermal delivery
- salt
- composition
- active agent
- cationic active
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
- G01N27/416—Systems
- G01N27/447—Systems using electrophoresis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Electrochemistry (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13252708P | 2008-06-19 | 2008-06-19 | |
US61/132,527 | 2008-06-19 | ||
PCT/EP2009/004316 WO2009153019A1 (en) | 2008-06-19 | 2009-06-16 | Composition for transdermal delivery of cationic active agents |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0909936A2 true BRPI0909936A2 (pt) | 2015-10-20 |
BRPI0909936B1 BRPI0909936B1 (pt) | 2019-07-23 |
Family
ID=40934213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0909936-0A BRPI0909936B1 (pt) | 2008-06-19 | 2009-06-16 | Composição para liberação transdérmica |
Country Status (16)
Country | Link |
---|---|
US (2) | US10881606B2 (pt) |
EP (2) | EP3308777A1 (pt) |
JP (2) | JP5620907B2 (pt) |
KR (1) | KR101656537B1 (pt) |
CN (2) | CN105456181A (pt) |
AU (1) | AU2009259601B2 (pt) |
BR (1) | BRPI0909936B1 (pt) |
CA (1) | CA2728975C (pt) |
ES (1) | ES2639576T3 (pt) |
IL (1) | IL210080A (pt) |
MX (1) | MX351262B (pt) |
NZ (1) | NZ590510A (pt) |
PL (1) | PL2285362T3 (pt) |
RU (1) | RU2517241C2 (pt) |
WO (1) | WO2009153019A1 (pt) |
ZA (1) | ZA201007576B (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8366600B2 (en) | 2008-06-19 | 2013-02-05 | Nupathe Inc. | Polyamine enhanced formulations for triptan compound iontophoresis |
WO2015058080A1 (en) * | 2013-10-17 | 2015-04-23 | Causwave Inc. | System and method for transdermal dialysis |
JP6564369B2 (ja) | 2013-12-09 | 2019-08-21 | デュレクト コーポレイション | 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法 |
WO2017119520A1 (ko) * | 2016-01-05 | 2017-07-13 | 바이오센서연구소 주식회사 | 역전기 투석을 이용한 마스크팩 및 그를 포함하는 키트 |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
BR112020010195A2 (pt) | 2017-12-20 | 2020-11-03 | Lts Lohmann Therapie-Systeme Ag | composição frigoestável para distribuição transdermal iontoforética de um composto de triptano |
CN111491619A (zh) | 2017-12-20 | 2020-08-04 | Lts勒曼治疗系统股份公司 | 用于离子电渗透皮递送曲坦化合物的耐低温的组合物 |
US11766558B2 (en) | 2018-07-30 | 2023-09-26 | Compass Health Brands Corp. | Biomedical electrode with anti-microbial properties |
WO2020212948A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
JP2022550463A (ja) | 2019-10-01 | 2022-12-01 | エンピリアン ニューロサイエンス, インコーポレイテッド | トリプタミン発現を調整する真菌の遺伝子操作 |
DE102020106115A1 (de) | 2020-03-06 | 2021-09-09 | Lts Lohmann Therapie-Systeme Ag | Iontophoretische Zusammensetzung zur Verabreichung von S-Ketamin |
CN115916215A (zh) * | 2020-04-16 | 2023-04-04 | 长矛治疗股份有限公司 | 迷幻剂衍生物的经皮微剂量递送 |
US20230219889A1 (en) | 2020-05-19 | 2023-07-13 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
CA3210966A1 (en) * | 2021-02-10 | 2022-08-18 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
WO2022212789A1 (en) * | 2021-03-31 | 2022-10-06 | Mycrodose Therapeutics Inc. | Transdermal system, formulation, and method for the therapeutic administration of a psychedelic agent |
CA3220214A1 (en) * | 2021-05-26 | 2022-12-01 | Abdelmalik Slassi | Hallucinogen-fatty acid combination |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US486902A (en) * | 1892-11-29 | Galvanic body-battery | ||
US222276A (en) * | 1879-12-02 | Improvement in combined galvanic and medicated pad | ||
CA1267937A (en) * | 1984-10-29 | 1990-04-17 | Joseph Bradley Phipps | Iontophoretic drug delivery |
CA2079315C (en) * | 1990-03-30 | 2003-04-15 | Joseph Bradley Phipps | Device and method for iontophoretic drug delivery |
DE4014913C2 (de) * | 1990-05-10 | 1996-05-15 | Lohmann Therapie Syst Lts | Miniaturisiertes transdermales therapeutisches System für die Iontophorese |
US5489624A (en) * | 1992-12-01 | 1996-02-06 | Minnesota Mining And Manufacturing Company | Hydrophilic pressure sensitive adhesives |
CA2126487C (en) * | 1993-06-23 | 2001-05-29 | Keiichiro Okabe | Iontophoresis device |
US6048545A (en) | 1994-06-24 | 2000-04-11 | Biozone Laboratories, Inc. | Liposomal delivery by iontophoresis |
CA2208332A1 (en) | 1996-06-20 | 1997-12-20 | Hisamitsu Pharmaceuticals Co., Inc. | Drug administration composition for iontophoresis |
GB9614098D0 (en) * | 1996-07-05 | 1996-09-04 | Orion Yhtymae Oy | Transdermal delivery of levosimendan |
DE19653606A1 (de) * | 1996-12-20 | 1998-06-25 | Roehm Gmbh | Haft- und Bindemittel aus (Meth)acrylatpolymer, organischer Säure und Weichmacher |
EP0898962A1 (en) | 1997-08-28 | 1999-03-03 | Becton, Dickinson and Company | Transdermal patches and methods for inactivating skin proteases |
US7258850B2 (en) * | 1999-05-04 | 2007-08-21 | Aradigm Corporation | Methods and compositions for treating erectile dysfunction |
JP4414517B2 (ja) * | 1999-09-01 | 2010-02-10 | 久光製薬株式会社 | イオントフォレーシス用デバイス構造体 |
US6496727B1 (en) * | 2000-05-31 | 2002-12-17 | Becton, Dickinson And Company | Medicament-loaded transdermal reservoir and method for its formation |
DE10035891A1 (de) * | 2000-07-24 | 2002-02-14 | Lohmann Therapie Syst Lts | Medizinischer Haftkleber mit einer zweiphasigen Klebermatrix aus Polyacrylaten und Polyaminsalzen |
DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
IT1319210B1 (it) * | 2000-10-13 | 2003-09-26 | Italiano Biochimico Lisapharma | Pellicola per la somministrazione dermica e transdermica di principiattivi. |
US6745082B2 (en) * | 2001-10-22 | 2004-06-01 | Jens Axelgaard | Current-controlling electrode with adjustable contact area |
JP4394444B2 (ja) * | 2001-10-24 | 2010-01-06 | パワー ペーパー リミティド | 活性物質の制御された皮膚内デリバリーのためのデバイス及び方法 |
US6745071B1 (en) * | 2003-02-21 | 2004-06-01 | Birch Point Medical, Inc. | Iontophoretic drug delivery system |
RU2326893C2 (ru) | 2003-04-16 | 2008-06-20 | Кориум Интернэшнл | Ковалентное и нековалентное сшивание гидрофильных полимеров и адгезивные композиции, полученные с ними |
PT1670433E (pt) * | 2003-10-10 | 2012-02-08 | Ferring Bv | Fórmula farmacológica transdérmica para a minimização de resíduos na pele |
NZ610790A (en) * | 2006-04-13 | 2015-05-29 | Nupathe Inc | Transdermal methods and systems for the delivery of anti-migraine compounds |
EP2040794A4 (en) | 2006-06-16 | 2010-10-20 | Transport Pharmaceuticals Inc | PHARMACEUTICAL FORMULATIONS FOR IONTOPHORETIC ADMINISTRATION OF TETRACYCLIN ANTIBIOTICS |
EP2063863A2 (en) * | 2006-08-29 | 2009-06-03 | Alza Corporation | Drug electrotransport with hydration measurement of hydratable reservoir |
JP2010520885A (ja) * | 2007-03-09 | 2010-06-17 | チェルシー・セラピューティクス,インコーポレイテッド | 線維筋痛症の治療のためのドロキシドパ及びその医薬組成物 |
US8366600B2 (en) * | 2008-06-19 | 2013-02-05 | Nupathe Inc. | Polyamine enhanced formulations for triptan compound iontophoresis |
-
2009
- 2009-06-16 AU AU2009259601A patent/AU2009259601B2/en not_active Ceased
- 2009-06-16 RU RU2010150880/15A patent/RU2517241C2/ru active
- 2009-06-16 US US12/737,209 patent/US10881606B2/en active Active
- 2009-06-16 EP EP17174972.4A patent/EP3308777A1/en not_active Withdrawn
- 2009-06-16 WO PCT/EP2009/004316 patent/WO2009153019A1/en active Application Filing
- 2009-06-16 JP JP2011513942A patent/JP5620907B2/ja active Active
- 2009-06-16 CN CN201610041838.4A patent/CN105456181A/zh active Pending
- 2009-06-16 EP EP09765599.7A patent/EP2285362B1/en active Active
- 2009-06-16 KR KR1020117001395A patent/KR101656537B1/ko active IP Right Grant
- 2009-06-16 CA CA2728975A patent/CA2728975C/en active Active
- 2009-06-16 ES ES09765599.7T patent/ES2639576T3/es active Active
- 2009-06-16 CN CN2009801204107A patent/CN102046157A/zh active Pending
- 2009-06-16 PL PL09765599T patent/PL2285362T3/pl unknown
- 2009-06-16 NZ NZ590510A patent/NZ590510A/xx not_active IP Right Cessation
- 2009-06-16 BR BRPI0909936-0A patent/BRPI0909936B1/pt active IP Right Grant
- 2009-06-16 MX MX2010013853A patent/MX351262B/es active IP Right Grant
-
2010
- 2010-10-25 ZA ZA2010/07576A patent/ZA201007576B/en unknown
- 2010-12-16 IL IL210080A patent/IL210080A/en active IP Right Grant
-
2014
- 2014-08-08 JP JP2014162654A patent/JP2015007080A/ja active Pending
-
2019
- 2019-12-16 US US16/715,972 patent/US10881607B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
IL210080A0 (en) | 2011-02-28 |
MX351262B (es) | 2017-10-06 |
CN105456181A (zh) | 2016-04-06 |
WO2009153019A1 (en) | 2009-12-23 |
CN102046157A (zh) | 2011-05-04 |
US20200113819A1 (en) | 2020-04-16 |
JP2011524389A (ja) | 2011-09-01 |
CA2728975C (en) | 2016-06-07 |
RU2517241C2 (ru) | 2014-05-27 |
RU2010150880A (ru) | 2012-06-20 |
NZ590510A (en) | 2012-08-31 |
KR101656537B1 (ko) | 2016-09-09 |
IL210080A (en) | 2016-03-31 |
ES2639576T3 (es) | 2017-10-27 |
KR20110028361A (ko) | 2011-03-17 |
JP2015007080A (ja) | 2015-01-15 |
JP5620907B2 (ja) | 2014-11-05 |
US10881606B2 (en) | 2021-01-05 |
CA2728975A1 (en) | 2009-12-23 |
EP2285362A1 (en) | 2011-02-23 |
US10881607B2 (en) | 2021-01-05 |
AU2009259601B2 (en) | 2014-09-18 |
EP2285362B1 (en) | 2017-08-09 |
MX2010013853A (es) | 2011-03-15 |
US20110111029A1 (en) | 2011-05-12 |
BRPI0909936B1 (pt) | 2019-07-23 |
EP3308777A1 (en) | 2018-04-18 |
AU2009259601A1 (en) | 2009-12-23 |
PL2285362T3 (pl) | 2017-12-29 |
ZA201007576B (en) | 2011-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0909936A2 (pt) | "composição para o envio transdérmico, em particular envio transdérmico iontoforético, de pelo menos um agente ativo catiônico ou um sal do mesmo" | |
BRPI0922584A2 (pt) | composição de fluido aquoso de tratamento de poço com atividade biocida, e, método para fornecer atividade biocida em um fluido de tratamento de poço | |
BRPI1014390A2 (pt) | composto de sal de amônio quaternário, composição medicinal, e, agente preventivo ou terapêutico | |
BRPI1013763A2 (pt) | Composto ou sal do mesmo, prodroga, composição farmacêutica, agente diminuidor da proteína de ligação de retinol 4, agente para a profilaxia ou tratamento de diabetes, e, uso de um composto | |
BRPI0906181A2 (pt) | "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer" | |
BR112012021905A2 (pt) | tratamento de nefrite lúpica usando laquinimod | |
BRPI0818244A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença | |
BRPI0914405A2 (pt) | "composto, composição fungicida e métodos para o controle de doenças de plantas" | |
BRPI0917458A2 (pt) | composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto | |
BRPI0907976A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
BRPI1011031A2 (pt) | sal de arginina de um agente ativo, composição líquida ou em gel farmaceuticamente aceitável, kit, método para tratamento de uma desordem neurológica e método para tratar ou amenizar a doença de parkinson em um paciente que necessite deste. | |
MX2010005385A (es) | Medicamentos topicos para la terapia antimicotica. | |
BRPI0907974A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
BRPI0822885A2 (pt) | Implemento para cuidado oral, método para administrar um agente ativo, e, kit para cuidado oral | |
BRPI0922452A2 (pt) | composto, composição farmacêutica, uso em um composto, e método para prevenir, tratar ou melhorar doenças ou condições dérmicas, ou distúrbios de ferimento cutâneo agudos ou crônicos. | |
BRPI0905388A2 (pt) | "composição farmacêutica; compostos e métodos de tratamento de infecção por arenavirus" | |
BRPI0811534A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto ou um sal farmaceuticametne aceitável do mesmo. | |
BR112012002246A2 (pt) | composto, composto ou sal farmaceutico aceitavel deste, composição farmaceutica, metodo para inibir, tratar e/ou reduzir o declinio cognitivol e/ou doença de akzhmer em um paciente | |
HK1137352A1 (en) | Therapeutic use of at least one botulic neurotoxin in the treatment of pain induced by at least one antineoplastic agent | |
BRPI0910759A2 (pt) | sistema e método para dispensar um agente de benefício hidrofóbicos a um substrato queratinoso, e, composição de enxágue corporal | |
CL2007003472A1 (es) | Sal fumarato de (alfa s,beta r)-6-bromo-alfa-[2-(dimetilamino)etil]-2-metoxi-alfa-1-naftalenil-beta-fenil-3-quinolinaetanol; proceso de preparacion; composicion farmaceutica; proceso de preparacion de la composicion farmaceutica; y uso en el tratamie | |
BRPI0908883A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças | |
BRPI1008727A2 (pt) | derivados de azol substituídos, composição farmacêutica contendo os derivados, e método para o tratamento de doença de parkinson usando os mesmos | |
BRPI0912112A2 (pt) | agente para suprimir um efeito indesejável de um analgésico do tipo opióide, agente terapêutico e/ou preventivo para dor, kit, composição farmacêutica, métodos para suprimir um efeito indesejável de um opióide, e para tratar e/ou prevenir a dor, uso de um composto e um opióide, composto, e, combinação | |
BRPI1006194A2 (pt) | "composição, fungicida para o controle de fungos nocivos fitopatogênicos, agente fungicida, método para o controle de fungos nocivos fitopatogênicos, semente e uso de fluopiram e metrafenona" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/07/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/06/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |